AAV2-Mediated Gene Therapy for Choroideremia: 5-Year Results and Alternate Anti-sense Oligonucleotide Therapy
Author:
Funder
Canadian Institutes of Health Research
Canada Foundation for Innovation
Foundation Fighting Blindness
Alberta Innovates Health Solutions
Publisher
Elsevier BV
Subject
Ophthalmology
Reference28 articles.
1. Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia;Xue;Nat Med,2018
2. Choroideremia gene therapy phase 2 clinical trial: 24-month results;Lam;Am J Ophthalmol,2019
3. Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial;Fischer;JAMA Ophthalmol,2019
4. Adeno-associated virus serotype 2-hCHM subretinal delivery to the macula in choroideremia: two-year interim results of an ongoing phase I/II gene therapy trial;Aleman;Ophthalmology,2022
5. Two-year results after AAV2-mediated gene therapy for choroideremia: the Alberta experience;Dimopoulos;Am J Ophthalmol,2018
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Sub-Retinal Delivery of Human Embryonic Stem Cell Derived Photoreceptor Progenitors in <em>rd10</em> Mice;Journal of Visualized Experiments;2023-10-06
2. Choroideremia: The Endpoint Endgame;International Journal of Molecular Sciences;2023-09-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3